EGFR inhibitors
Checkpoint Therapeutics Announces $10M Registered Direct Offering of Common Stock
The company will use the funds to support the manufacturing and pre-commercial activities for its lead candidate cosibelimab.
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
Bridge Biotherapeutics Starting Phase I/II Trial of Fourth-Generation EGFR TKI in NSCLC
The FDA cleared the firm's IND to evaluate BBT-207 among EGFR-mutated lung cancer patients resistant to earlier-generation EGFR inhibitors.
Early studies of KRAS inhibitors from Loxo Oncology, Genentech, and Innovent suggest newer drugs have activity in KRAS G12C-resistant patients.
Deka Biosciences Begins Phase I Trial for 'Diakine' in EGFR-Mutant Solid Tumors
The firm wants to study its investigational agent DK210 (EGFR) in 60 EGFR-mutant cancer patients including those with NSCLC, pancreatic cancer, and colorectal cancer.
Aug 11, 2022
Jul 28, 2022
May 20, 2022